Current TB drugs are both cheap and effective, yet the death rate due to TB continues to be extraordinarily high. Two factors limit the usefulness of existing drugs – the long courses of therapy needed for cure, which in turn require substantial supporting infrastructure to deliver care, and the rising rate of drug resistance. Our lab is interested in both understanding how older antibiotics work in an effort to combat resistance, and contributing to the development of new anti-TB drugs.